Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL by John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O’Brien

Get full text

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US r... by Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley